MYGN Q1 2025 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q1 2025 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$196M-3.1% YoY

Gross Profit

$134M68.5% margin

Operating Income

-$29M-14.8% margin

Net Income

-$100,000-0.1% margin

EPS (Diluted)

$-0.00

QoQ Revenue Growth

-7.0%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$25M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$301M

Stockholders' Equity

$705M

Cash & Equivalents

$92M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$196M	$202M	-3.1%
Gross Profit	$134M	$138M	-2.5%
Operating Income	-$29M	-$28M	-3.9%
Net Income	-$100,000	-$26M	+99.6%

Geographic Segments

UNITED STATES

$182M93%

Non-US

$14M7%